

# **KAPISH JAIN & ASSOCIATES**

# CHARTERED ACCOUNTANTS

**Head Office:** 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone: +91-11-43708987 Mobile: +91 9971 921466 | Email: ca.kapish@gmail.com | Website: www.kapishjainassociates.com; www.cakja.com

Independent Auditor's Review Report on Standalone Unaudited Financial Results for the half year ended 30 September 2025 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Ambey Laboratories Limited

- 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("Statement") of Ambey Laboratories Limited("the Company") for the half year ended 30 September 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.
- 2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. During the half year ended on 30 September 2025, the Company issued 1,08,69,565 Convertible Equity Warrants to public category investors at an issue price of Rs. 46/- per warrant, against receipt of 25% of the allotment money, in accordance with Sections 42 and 62(1)(c) of the Companies Act, 2013 and other applicable provisions. The warrants remain outstanding and pending conversion as at the reporting date.

The 25% money received against these warrants has been utilized for the purposes detailed in the table below.

Rs. In Lakhs

Object of issue	Amount received (25% of total value)	Amount utilized till September 30, 2025	Amount unutilized till September 30, 2025	Deviation (if any)
The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.		1,250.00		N/A

# For KAPISH JAIN & ASSOCIATES

NEW DELHI

Chartered Accountants Firm Registration No. 022743N

CA Kapish Jain

Partner

M. No.: 514162

UDIN: 25514162BMJVGE8958

Place: New Delhi

Date: 14 November 2025

## AMBEY LABORATORIES LIMITED

Regd. Office: Ground Floor, Property No.555 Tarla Mohalla, Ghitorni, South West Delhi, India, 110030

Corp. Office: B18/9, Dif Phase -1 Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002
CIN: L74899DL1985PLC020490, Email:cs@ambeylab.com
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS

FOR THE HALF YEAR ENDED 30 SEPTEMBER 2025

SL No	Particulars		. Half year ended	Y	ear ended
	an ocume 5	30.09.2025	31.03.2025	30.09.2024	31.03.2025
1	Income	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	a) Revenue from operations				
	b) Other income	6,817.59	6,361.76	6,765.23	13,126,99
	Total income	13.37	114.16	77.45	191.6
2	Expenses	6,830.96	6,475.92	6,842,68	13,318,60
-	a) Cost of material consumed				110.00
		6,176.51	5,764.22	6,118.84	11,883.06
		(226.46)	8.18	(191.51)	(183.33
	c) Employee benefits expense d) Finance costs	77.01	102.54	72.45	174,99
		192.11	171.12	120.04	291.16
	, -1	110,09	75.80	178.50	254.30
	The second supported to	201.13	111.42	183.17	294.59
-	Total expenses	6,530,39	6,233,28	6,481,49	12,714,77
3	Profit/(loss) before exceptional item & tax (1-2)	300.57	242.64	361.19	603.83
	Exceptional Items		-	201112	000,00
5	Profit/(loss) before tax (3-4)	300.57	242.64	361.19	603.84
W.	Tax expense	56.52	57.66	56.27	113.95
	Deferred tax charge/ (benefit) MAT credit entitlement	38.40	60.93	64.63	125.56
	The state of the s	(56.52)	(57.66)	(56.27)	(113.95)
7	Tax expense	38.40	60.93	64.63	125.56
	Net Profit/(Loss) after tax (5-6)	262.17	181.71	296,56	478.27
	Paid-up Equity Share Capital (Face value of Rs.10/- each)	2,494.68	2,494.68	2,494.66	2,494.68
10	Reserves (excluding revaluation reserve)				4,090,35
10	Earnings per equity share				4.000.0
	[Nominal value per share Rs. 10] (not annualised, except year end)				
	Basic earnings per share (in ₹)	1.05	0.78		7
	Diluted earnings per share (in ₹)	1.05	0.78	1.38	2.06
		1.00	0.78	1.38	2.06

- The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 14 November 2025.
- The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Company has a single reportable segment as per the Accounting Standard 17.

For and Behalf of Board of For and Behalf of Dould of Ambey Laboratories Limited

hily

BORATOR

Archit Gupta Whole Time Director DIN 00378409

STANDALONE STATEMENT OF ASSETS & LIABILITIES Particulars		
	Standa	alone
EQUITY AND LIABILITIES	As at 30.09.2025	As at 31,03,202
1 Shareholders' funds		
a) Share capital		100
b) Reserves and surplus	2,494,68	2,494.6
o) Acord ves and surpage	5,402.51	77.00
c) Money Received Against share warrant	1,250.03	5,140.3
Total Equity	9,147.22	7,635.0
2 Share Application Money Pending Allotment		7,905,054
A 24.1 mg		
3 Liabilities		
Non-current liabilities		
a) Long-Term Borrowings	1,002.41	
b) Deferred tax liabilities	1.893.41	1,074.8
c) Other long-term liabilities		
d) Long-term provisions		
Total non-current liabilities	53.59	53.59
Current liabilities	1,947.00	1,128.4
a) Short-Term Borrowings		
b) Trade payables	2,108.78	3,009.48
(i) Total outstanding dues of micro enterprises and small enterprises; and		
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	69.53	94.49
c) Other current liabilities	468,95	568.58
d) Short-term provisions	155.41	192.75
Total current liabilities	109.77	92,47
The state of the s	2,912.44	3,957.77
Total equity and llabilities	14,006.66	
Assets	14,000.00	12,721.21
Non-current assets		
a) Property, plant and equipment		
(i) Property ,pant and equipment		
(i) Intangible assets	2,150.87	2,253.89
(iii) Capital work-in-progress	50.81	57.70
b) Non-current investments	1,717.75	1,566.42
c) Deferred tax assets (Net)	10.00	
d) Long-term loans and advances	103.65	142.06
e) Other non-current assets	411.22	47.93
Total non-current assets		
Current assets	4,444.30	4,068,00
a) Current investment		
b) Inventories		
c) Trade receivables	3,061.24	2,991.32
d) Cash and bank balances	4,997.68	4,043.19
	164.62	176.30
e) Short-term loans and advances	1,283.11	1,354.95
f) Other current assets	55.71	
Total current assets	9,562,36	87.45 8,653.21
Total assets		
	14.006.66	12,721,21

For and Behalf of Board of Ambey Laboratories Limited BORATOR

Archit Gupta Whole Time Director DIN 00378409

6	STANDALONE STATEMENT OF CASH FLOWS		
		Fourth Late	Rs. In Lai
A.	Cash flow from operating activities	For the half y 30.09.2025	
	Profit/(loss) before tax	50.03.2025	30.09.2024
	Adjustments for :	300.56	
	Depreciation and amortisation expense	300.36	361
	Net (profit)/ loss on disposal of property, plant and equipment	Lines I	
	Interest expense and finance cost	110.09	120
	Unrealised foreign currency (gain)/loss		(1,
	Interest income	192.11	178.
			(0.0
	Channes in a second at the control of the control o	(4.29)	(12.5
	Changes in assets and itabilities (Increase) / Decrease in inventories	598.47	645.
	(Increase) / Decrease in trade receivables		
	(Increase) / Decrease in Irane receivables	(69.92)	(649.8
- 1	(Increase) / Decrease in long term loans and advances (Increase) / Decrease in short term loans and advances	(954.49)	(3,574.
	(Increase) / Decrease in other assets	(363.28)	(422.9
1	Increment / (deceases) in the control of the contro	87.75	(93.2
1	Increase / (decrease) in trade payables	31.75	(98.6
1	Increase / (decrease) in short term provisions	(124.59)	1,192.9
li	Increase / (decrease) in long term provisions mcrease / (decrease) in other liabilities		52.4
0	ash generated from operating activities		14.3
T	axes paid (net of refunds)	(37.33)	169.4
N	et cash generated from operating activities	(831.64)	(2,764.9
1	cust generated from operating activities	1.37	(33.3
1)	ash Flow from Investing Activities Purchase) Sale of Fixed Assets	(830,27)	(2,798.3
In	vestment in subsidiary companies	(151.51)	
In	vestment in Fixed Deposit	(10.00)	(496.89
In	terest received		
N	et cash generated from/(used in) investing activities	1.79	(368.84
	and the string activities	(155,43)	12.59
Int	ash flows from financing activities terest & Finance Cost	(155,43)	(853.14
Pn	oceeds from issues of equity shares	(192.11)	178.50
Pn	occeds of long term borrowings		4,005.44
(R	depayments ) / proceeds of short term borrowings	818.59	(249.38
PR	oceeds from issues of share warrants	(900.70)	84.18
Ne	t cash generated from/(used in) financing activities	1,250.03	84.18
		975.81	3,661.74
INC.	t increase/(decrease) in cash and cash equivalents (A+B+C)		
Car	sh and cash equivalents at the heginning of year	(9.89)	10.22
Ca	sh and cash equivalents at the end of year	72.76	36.50
The	above statement of cash flow has been prepared under the 'Indirect Method'.	62.87	46,72

During the FY 2025-26, the Company Issued 1,08,69,565 Convertible Equity Warrants to public category investors at an issue price of Rs. 46/- per warrant, against receipt of 25% of the all otmen money, in accordance with Sections 42 and 62(1)(c) of the Companies Act. 2013 and other applicable provisions. The warrants remain outstanding and pending conversion as at the reporting date.

The 25% money received against these warrants has been utilised for the purposes detailed in the table below.

The funds were utilised towards general corporate purposes advances of		Amount utilized till 30 September 2025	Amount unutilized till 30 September 2025	Deviation (if any)
upporting ongoing capital expenditure; and land-related advances made through the Subsidiary to acilikate future expansion and development plans.	1250.00	1250.00		
	1250.00	1250.00		-

8 The standalone financial results include the results for the half year ended 31 March 2025, being the balancing figures between the audited figures in respect of the full financial year ended 31 March 2025 and the figures for the half year ended 30 September 2024.

9 The figures for the previous period have been regrouped / rearranged / reclassified wherever necessary.

BORATOR

Ambey Laboratories Limite Aubil 16

For and Behalf of Board of

Archit Gupta Whole Time Director DIN 00378409



# **KAPISH JAIN & ASSOCIATES**

## CHARTERED ACCOUNTANTS

**Head Office:** 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone: +91-11-43708987 Mobile: +91 9971 921466 | Email: ca.kapish@gmail.com | Website: www.kapishjainassociates.com; www.cakja.com

Independent Auditor's Review Report on Consolidated Un-audited Financial Results for the six months ended 30 September 2025 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Ambey Laboratories Limited

- 1. We have reviewed the accompanying Statement of Consolidated Un-audited Financial Results of **Ambey Laboratories Limited** ("the Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") for the six months ended 30 September 2025 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.
- 2. This statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related unaudited interim financial information which has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. The Statement includes the results of following entity:

S. No.	Name of the entity	Relation
1	Dhansa Green Energy Private Limited (w.e.f. August 14, 2025)	Subsidiary Company

- 5. The holding company acquired 100% stake in Dhansa Green Energy Private Limited ("the subsidiary company"), with effect from 14th August 2025. As a result, the consolidated figures for the six-months ended 30 September 2025, include subsidiary's financials from that date onward. Consequently, comparative figures for the six-months ended 30 September 2024, and for the six months and year ended March 2025 are not presented in these results, as subsidiary companies were not part of the group during those periods.
- 6. The consolidated financial results include the financial results of subsidiary, whose financial statements/financial information reflect total assets of Rs. 2.81 lacs & net assets of Rs. 0.15 lacs as at 30 September 2025 and total revenue of Rs. nil lacs & total net profit / (loss) after tax of Rs. (0.15) lacs for the six months ended 30 September 2025 and cashflow inflow (net) of Rs. 73.76 lacs, as considered in the unaudited consolidated financial results which have been reviewed by their respective independent auditors. The independent auditor's reports on financial statements/ financial information of these entities have been furnished to us by the management.

Our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

Our conclusion on the consolidated unaudited financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

7. Based on our review conducted as stated above, nothing has come to our attention that that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.



8. During the FY 2025-26, the holding company issued 1,08,69,565 Convertible Equity Warrants to public category investors at an issue price of Rs. 46/- per warrant, against receipt of 25% of the allotment money, in accordance with Sections 42 and 62(1)(c) of the Companies Act, 2013 and other applicable provisions. The warrants remain outstanding and pending conversion as at the reporting date.

The 25% money received against these warrants has been utilized for the purposes detailed in the table below.

Rs. In Lakhs

Object of issue	Amount received (25% of total value)	Amount utilized till September 30, 2025	Amount unutilized till September 30, 2025	Deviation (if any)
The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	1,250	1,250	-	N/A

# For KAPISH JAIN & ASSOCIATES

Chartered Accountants Firm Registration No. 022743N

CA Kapish Jain Partner M. No.: 514162

UDIN: 25514162BMJVGF2182 Acco

NEW DELHI

Place: New Delhi

Date: 14 November 2025

## AMBEY LABORATORIES LIMITED

Regd. Office: Ground Floor, Property No.555 Taria Mohalla, Ghitorni, South West Delhi, Delhi, India, 110030

Corp. Office: B18/9, Dif Phase -1 Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002

# CIN: L74899DL1985PLC020490, Emailts:@ambeylah.com STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2025

			Half year ended		Year ended
I. No	Particulars	30.09,2025	31.03.2025	30.09.2024	31.03.2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income				
	a) Revenue from operations	6,817.59			
	b) Other income	13.37			
	Total income	6,830.96			
2	Expenses				
	a) Cost of material consumed	6,176,51			
	h) Changes in inventories of work-in-progress, finished goods	(226.46)			
	c) Employee benefits expense	77.01			
	d) Finance costs	192.11			
	e) Depreciation and amortisation expense	110.09			
	f) Other expenses	201.28			
	Total expenses	6,530,54			
3	Profit/(loss) before exceptional item & tax (1-2)	300.42			
4	Exceptional Items				
5	Profit/(loss) before tax (3-4)	300.42			
6	Tax expense	56.52	-		
	Deferred tax charge/ (benefit)	38.40			
	MAT credit entitlement	(56.52)			
	Tax expense	38.40			
7	Net Profit/(Loss) after tax (5-6)	262.02			
8	Paid-up Equity Share Captial (Face value of Rs.10/- each)	2,494.68			
9	Reserves (excluding revaluation reserve)				
10	Earnings per equity share				
	[Nominal value per share Rs. 10] (not annualised, except year end)				
	Basic earnings per share (in ₹)	1.05			
	Diluted earnings per share (in ₹)	1.05			

- 1 The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 14 November 2025.
- 2 The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Compa Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The Holding Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Holding Company has a single reportable segment as per the Accounting Standard 17.

For and Behalf of Board of Ambey Laboratories Limited wer

ORATOR

Archit Gupta Whole Time Director DIN 00378409

CONSOLIDATED STATEMENT OF ASSETS & LIABILITIES		
Particulars	Consoli	idated
	As at 30.09.2025	As at 31.03.2025
EQUITY AND LIABILITIES 1 Shareholders' funds	17-13-27	
a) Share capital	2,494.68	
b) Reserves and surplus	5,402.36	
c) Money Received Against share warrant	1,250.03	
Total Equity	9,147.07	
2 Share Application Money Pending Allotment		
3 Liabilities		
Non-current liabilities		
a) Long-Term Borrowings	1,895.02	1
b) Deferred tax liabilities		
c) Other long-term liabilities		
d) Long-term provisions	53.59	
Total non-current liabilities	1,948.61	
Current liabilities		
a) Short-Term Borrowings	2,108.78	
b) Trade payables		
(i) Total outstanding dues of micro enterprises and small enterprises; and	69.53	
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	468.95	
c) Other current liabilities	156.76	
d) Short-term provisions	109.77	
Total current liabilities	2,913.79	
Total equity and liabilities	14,009.47	
Assets		
1 Non-current assets		
a) Property, plant and equipment		
(i) Property pant and equipment	2,150.87	
(i) Intangible assets	50.81	
(iii) Capital work-in-progress	1,721.76	
b) Non-current investments		
c) Deferred tax assets (Net)	103.65	
d) Long-term loans and advances	119.02	
c) Other non-current assets		
Total non-current assets	4,146,11	
2 Current assets	- ALTOIT	
a) Current investment		
b) Inventories	3,061.23	
c) Trade receivables	4,997,68	
d) Cash and bank balances	165.62	
e) Short-term loans and advances	1.583.12	
f) Other current assets	55.71	
Total current assets	9,863,36	
Total assets	14,009.47	-

For and Behalf of Board of Ambey Laboratories Limited

ORATORIA

Archit Gupta Whole Time Director DIN 00378409

T	CONSOLIDATED STATEMENT OF CASH FLOWS		Rs. In Lakhs
1	CONSTRUCTION OF CHARLES OF CHARLES OF CONTRACT OF CONT	For the half ye	ear ended
		30.09.2025	30.09.2024
Α.	Cash flow from operating activities Profit/(loss) before tax	300.41	
	Adjustments for:	110.09	
	Depreciation and amortisation expense	192.11	
	Interest expense and finance cost Interest income	(4.29)	
	Consolidated adjustment	7,492.97	
	Consolidated adjustment	8,091.29	-
	Changes in assets and liabilities (Increase) / Decrease in inventories	(3,061.23)	
	(Increase) / Decrease in trade receivables	(4,997.58)	
	(Increase) / Decrease in long term loans and advances	(119.02)	
	(Increase) / Decrease in short term loans and advances	(1,154.40)	
	(Increase) / Decrease in other assets	(55.71)	
	Increase / (decrease) in trade payables	538.50	
	Increase / (decrease) in short term provisions	34.54	
	Increase / (decrease) in long term provisions	53.59	
	Increase / (decrease) in other liabilities	156.76	-
	Cash generated from operating activities Taxes paid (net of refunds)	(513.36) (353.48)	1
	Net cash generated from operating activities	(866,84)	
В.	Cash Flow from Investing Activities (Purchase) Sale of Fixed Assets	(4,033.54)	
	(Purchase) Sale of Current Investment	4401.00	
	Investment in Fixed Deposit	(101.75)	
	Interest received	(4,131,00)	
	Net cash generated from/(used in) investing activities	(4,151.00)	
c.	Cash flows from financing activities Interest & Finance Cost	(192.11)	
	Proceeds from issues of equity shares	-	
	Proceeds of long term borrowings	1,895.02	
	(Repayments) of long term borrowings	-	
	( Repayments ) / proceeds of short term borrowings	2,108.77	
	Proceeds from issues of share warrants	1,250.03	-
	Net cash generated from/(used in) financing activities	5,061.71	
	Net increase/(decrease) in cash and cash equivalents (A+B+C)	63.87	
	Cash and cash equivalents at the beginning of year	-	
	Cash and cash equivalents at the end of year	63.87	

The above statement of cash flow has been prepared under the 'Indirect Method'.

7 During the FY 2025-26, the holding company issued 1,08,69,565 Convertible Equity Warrants to public category investors at an issue price of Rs. 46/- per warrant, against receipt of 25% of the allotment money, in accordance with Sections 42 and 62(1)(e) of the Companies Act, 2013 and other applicable provisions. The warrants remain outstanding and pending conversion as at the reporting date.

The 25% money received against these warrants has been utilised for the purposes detailed in the table below.

orting ongoing capital expenditure; and land-related advances made through the Subsidiary tate future expansion and development plans.	Amount received	Amount utilized till 30 September 2025	Amount unutilized till 30 September 2025	Deviation (if any)
The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances made through the Subsidiary to facilitate future expansion and development plans.	1250.00	1250.00		
Total	1250.00	1250.00		

8 The figures for the previous period have been regrouped / rearranged / reclassified wherever necessary.

RATOR

For and Behalf of Board of Ambey Laboratories Limited

Archit Gupta Whole Time Director DIN 00378409

## Amount in Lakhs

		T	opikable only for half-yearly fi	term to a Sendar	ad late assessment	Granata Balki																																	
	7		Maranan da madanda		in to the control of																																		
																e d elike pakturusken.	plant at a control	epaklurabrida	p palap saban ab	ent-water and carp	remaigner bilberhilm		. troutak melaba	nleash.on; wathripsister	- enter white with														
	immik dake Internation	and what tap		Driabal Brauchpak		Ortalisal Dr. mortispash.		Drink of the marks park		Delaik of the marringanis		Driah al Sv mur Inpah.		Driah al By murbipals		Orland By murinpair.		Ditabal Braselepah				Shrallbridge		VA. d broken	Outraliant Correla		biograms as as I	entropis sursti mater	l kreenken	ulrathern neuerland		mpst, manne			Driabal	Deleasyele o	apade a polyanae e	are wheels	
		ROH	Harr	ROH	Pridambigal Browningsdomin Bridam relations was	'spraintémpuls lumater	Driak d almorides pakturader	polytomateria. I approxisher and correlate	Probe specific	pakturaleriden hillrad sender	Medegaler for idleder no. apenie	Maratar maghropades pres		laboral States	terus.		Age v kontatile kan mikralise in Prakesire operial isen kensum		wn.																				
•			immis Forest and clarity		Correct Continue as harbotics s let receive high the parties.	And penn wen				78.0		ARM		BA17																									
•	rdn		immels Forcer Forder lands		Correct Combiner as sharks been before a bidd the parties.	Robertpauroan				78.0		VA-488	71.9																										
•			Duru Serum Andrimin		Correse Clandor, ar a sharbolors. Selector half-life parter.	Wild pane wen				-		THEO	AL P	27,813																									
	nt n		Could East a		WE DO Johnson	Resource		V.=				.=	884	1.00																									
			Fried Carlo		Forein	Brancher		V.0					884	100																									
	nt n		Same Bade		Remain	Bransler						L=		1.00																									
	-d-		Conditions o		Onlereforth	Branular		7.0				1=																											
			Name days		DJ DE	Bransler		V.0				4.5										_																	
																						_																	
	of o		Fernando Coloria Fernando Olari Domi		because d Oncin	Oralle becales		12				ŀ	10	100	L" UI LY	L <sup>21</sup> UI 19	L) UI 19	C UI C	LU MI KY	L <sup>0</sup> III IV	L <sup>0</sup> III Ly	Ci Wi Cy	C) U1 15	Lii ui se	C) 11 12 15 15 15 15 15 15 15 15 15 15 15 15 15														

Mari. I Francisk ethikand ar inisan harpameria silkansi ar ismikleras agthripadag pass Herran, qeragara bagkdari ya isang ismiknet y

his endered configuration at the confidence of the confidence of the configuration and the property of the confidence of

A Mineral hands for an interaction of the resemble of the second of the

Character or militerated or an emphasis (I), the observation has been becaused by more depleted in the executive ment has been like

Seption of the section of the sectio

konstinantionelyn. Henes far unter op de var rauf op hattie weelyn en le gynglod o de proping grow, he eder op de far op hattie van de var god on de de pepting grow op hattie de var far de far van de gynglod of de pepting grow op hattie de var de far van de far va

kiraval arak va etirapakturadar

a. Vergge plancke at substitute park to make a suppressive for and consider shallong be related. When the related park have been appreciable and consider the park of the related and the related at t

In the description of the section would describe a specific properties the sales "Noted a delegate bureation and because of the properties".
 Charles the result in consistency to the behavior of the sales are a superior of the sales and the sales are a superior of the sales are a supe